English health service sets out two-year recovery plan for emergency care

(Adds drug's pricing, details, background) Dec 22 (Reuters) - The U.S. Food and Drug Administration (FDA) on Thursday approved Gilead Sciences Inc's Sunlenca therapy for HIV infections, paving the way

Dec 22 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Amgen, Coupa Software and Enphase Energy, on Thursday. HIGHLIGHTS

(Adds agency comment, background) Dec 22 (Reuters) - England reported 94 deaths, including those of 21 children, from scarlet fever and invasive strep A infections so far this season the UK Health

Dec 22 (Reuters) - UK Health Security Agency: * UK SAYS SO FAR THIS SEASON THERE HAVE BEEN 94 DEATHS ACROSS ALL AGE GROUPS IN ENGLAND DUE TO SCARLET FEVER AND INVASIVE GROUP A STREP * UK SAYS SO FAR

(Reuters) - The British government said on Thursday there have been 94 deaths due to scarlet fever and invasive group Strep A infections across all age groups in England so far this season. The UK

BEIJING (Reuters) - More than 5,000 people are probably dying each day from COVID-19 in China, health data firm Airfinity estimated, offering a dramatic contrast to official data from Beijing on the

Dec 22 (Reuters) - Logistics Development Group PLC : * LOGISTICS DEV GRP - ALLIANCE PHARMA PLC INVESTMENT * LOGISTICS DEVELOPMENT GROUP - BUYS 12.8 MILLION ORDINARY SHARES IN ALLIANCE PHARMA PLC AT AN

Dec 22 (Reuters) - ImmuPharma PLC: * IMMUPHARMA PLC - END OF YEAR UPDATE * IMMUPHARMA PLC - CONTINUES TO WORK WITH PARTNER AVION & EXTERNAL ADVISORS, ON PREPARATIONS AROUND PROPOSED UPDATED P140

Dec 22 (Reuters) - OKYO Pharma Ltd: * U.S. FDA CLEARANCE OF IND APPLICATION FOR OK-101 * OKYO PHARMA ANNOUNCES U.S. FDA CLEARANCE OF IND APPLICATION FOR OK-101 FOR TREATMENT OF DRY EYE DISEASE * PHASE

Dec 22 (Reuters) - Destiny Pharma PLC: * DESTINY PHARMA PLC - YEAR END TRADING UPDATE * DESTINY PHARMA PLC - TO FINALISE OUR PHASE 3 PLANS FOR XF-73 NASAL AND INTENSIFY PARTNERING DISCUSSIONS *